Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re ...

Congress in Spain were a major feature of research news last week, including those from Pfizer on it ponsegromab in cancer ...

Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

Goldman Sachs analyst Chris Shibutani has maintained their bullish stance on ROIV stock, giving a Buy rating today. Chris Shibutani has given ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...

Roivant Sciences Ltd. has sold another company, this time offering up Dermavant Sciences Ltd. to Organon & Co. for $1.2 ...

18, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, and Dermavant Sciences Ltd. announced today that ...

Women’s health specialist Organon has entered into a definitive agreement to acquire Dermavant Sciences, a Roivant company.